By the Numbers

10 Updates for Crohn’s and Colitis Awareness Week

December 1 to December 7 marks Crohn’s & Colitis Awareness Week. First created by U.S. Senate Resolution 199 in November 2011, this national initiative aims to express appreciation for the family members, caregivers, health professionals and researchers who support patients with Crohn’s disease and ulcerative colitis, and also seeks to bring the inflammatory bowel disease community together in a shared goal of educating the public about IBD.

This week, the Crohn’s and Colitis Foundation is helping to spread awareness by inviting patients to share their stories on Twitter using #myIBD and #IBDVisible.

In recognition of Crohn’s and Colitis Awareness Week, the editors of Healio Gastroenterology and Liver Disease have compiled a list of 10 updates in IBD research and patient care.

Cannabis oil improves Crohn’s symptoms, QOL, but not inflammatory markers

Using cannabidiol, researchers showed symptomatic and quality of life improvement, but using endoscopic measures, they did not see improvement in inflammatory markers and only a trend toward inflammation improvement, according to a researcher at UEG Week 2018. READ MORE.

Psoriasis linked to increased risk for Crohn’s, UC

Patients with psoriasis are increasingly linked to risks for Crohn’s disease, ulcerative colitis and a combination of the two diseases, according to a review study published in JAMA Dermatology. READ MORE.

Clinical response within 4 months may predict sustained UC remission with Entyvio

Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases. READ MORE.

Subcutaneous vedolizumab shows promise for UC

Vedolizumab delivered subcutaneously for maintenance of ulcerative colitis, differing from the current intravenous delivery, showed similar efficacy to traditional delivery and superiority to placebo in a study presented during UEG Week 2018. READ MORE.

Humira levels linked to biologic Crohn’s remission

Patients with optimized Humira drug levels were more likely to achieve biologic remission, according to research published in Inflammatory Bowel Diseases. READ MORE.

Xeljanz appears safe, effective for long-term UC treatment

PHILADELPHIA — Xeljanz, an oral Janus kinase inhibitor, showed efficacy and safety in the treatment of ulcerative colitis in a 24-month, open label extension study, according to study results presented at the American College of Gastroenterology Annual Meeting. READ MORE.

Oral antibiotic for Crohn’s induces remission in phase 3 study

Data from a phase 3 study centered on RHB-104 showed positive safety and efficacy results for the treatment of Crohn’s disease.

The manufacturer, RedHill Biopharma, said the drug was superior to placebo in achieving remission at 26 weeks, according to a press release. READ MORE.

Abrilumab induces remission, healing in moderate to severe UC

Abrilumab, an anti-alpha-4 beta-7 antibody, helped induce remission, clinical response and mucosal healing in patients with moderate to severe ulcerative colitis, according to research published in Gastroenterology. READ MORE.

Worse Crohn’s disease activity causes more sleep disturbances

Patients with worse Crohn’s disease activity experience more disturbances to their sleep patterns, according to research published in Inflammatory Bowel Diseases. READ MORE.

More research needed to test comparative effectiveness of UC treatments

Induction treatment with various biologic agents improved quality of life among patients with ulcerative colitis, according to research published in Alimentary Pharmacology & Therapeutics. READ MORE.

December 1 to December 7 marks Crohn’s & Colitis Awareness Week. First created by U.S. Senate Resolution 199 in November 2011, this national initiative aims to express appreciation for the family members, caregivers, health professionals and researchers who support patients with Crohn’s disease and ulcerative colitis, and also seeks to bring the inflammatory bowel disease community together in a shared goal of educating the public about IBD.

This week, the Crohn’s and Colitis Foundation is helping to spread awareness by inviting patients to share their stories on Twitter using #myIBD and #IBDVisible.

In recognition of Crohn’s and Colitis Awareness Week, the editors of Healio Gastroenterology and Liver Disease have compiled a list of 10 updates in IBD research and patient care.

Cannabis oil improves Crohn’s symptoms, QOL, but not inflammatory markers

Using cannabidiol, researchers showed symptomatic and quality of life improvement, but using endoscopic measures, they did not see improvement in inflammatory markers and only a trend toward inflammation improvement, according to a researcher at UEG Week 2018. READ MORE.

Psoriasis linked to increased risk for Crohn’s, UC

Patients with psoriasis are increasingly linked to risks for Crohn’s disease, ulcerative colitis and a combination of the two diseases, according to a review study published in JAMA Dermatology. READ MORE.

Clinical response within 4 months may predict sustained UC remission with Entyvio

Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases. READ MORE.

Subcutaneous vedolizumab shows promise for UC

Vedolizumab delivered subcutaneously for maintenance of ulcerative colitis, differing from the current intravenous delivery, showed similar efficacy to traditional delivery and superiority to placebo in a study presented during UEG Week 2018. READ MORE.

Humira levels linked to biologic Crohn’s remission

Patients with optimized Humira drug levels were more likely to achieve biologic remission, according to research published in Inflammatory Bowel Diseases. READ MORE.

Xeljanz appears safe, effective for long-term UC treatment

PHILADELPHIA — Xeljanz, an oral Janus kinase inhibitor, showed efficacy and safety in the treatment of ulcerative colitis in a 24-month, open label extension study, according to study results presented at the American College of Gastroenterology Annual Meeting. READ MORE.

PAGE BREAK

Oral antibiotic for Crohn’s induces remission in phase 3 study

Data from a phase 3 study centered on RHB-104 showed positive safety and efficacy results for the treatment of Crohn’s disease.

The manufacturer, RedHill Biopharma, said the drug was superior to placebo in achieving remission at 26 weeks, according to a press release. READ MORE.

Abrilumab induces remission, healing in moderate to severe UC

Abrilumab, an anti-alpha-4 beta-7 antibody, helped induce remission, clinical response and mucosal healing in patients with moderate to severe ulcerative colitis, according to research published in Gastroenterology. READ MORE.

Worse Crohn’s disease activity causes more sleep disturbances

Patients with worse Crohn’s disease activity experience more disturbances to their sleep patterns, according to research published in Inflammatory Bowel Diseases. READ MORE.

More research needed to test comparative effectiveness of UC treatments

Induction treatment with various biologic agents improved quality of life among patients with ulcerative colitis, according to research published in Alimentary Pharmacology & Therapeutics. READ MORE.

    See more from Ulcerative Colitis Resource Center